|
Synonyms: ABT-874 | J-695 | J695 | Ozespa
Compound class:
Antibody
Comment: Briakinumab is a recombinant, fully human, IgG1 investigational monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23. Peptide sequences matching those of briakinumab are claimed in patent US6914128 'Human antibodies that bind human IL-12 and methods for producing' [2].
View more information in the IUPHAR Pharmacology Education Project: pericyazine |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Clinical development for RA has been terminated. | |
| Crohn's disease |
Disease Ontology:
DOID:8778 OMIM: 266600 Orphanet: ORPHA206 |
Clinical development for CD has been terminated. | |
| Relapsing-remitting multiple sclerosis |
Disease Ontology:
DOID:2378 |
Clinical development for RRMS has been terminated. | |
